This study measured the precision of a quantitative laboratory-developed real-time PCR test for cytomegalovirus performed at three different clinical laboratories that use the same methodology. The overall standard deviation (adjusted for analyte level) was 0.18 log 10 copies/ml, and there was no significant relationship between standard deviation and analytical measuring range.
Previous studies have shown that laboratory-developed viral load (VL) assays differ dramatically among various instruments, reagents, and calibration schemes (5, 9, 10, 12) . For this reason, it is strongly recommended that individual patient VLs should always be tracked using the same methodology at the same laboratory. Furthermore, it is important to understand the precision of the assay to clarify when a difference between two subsequent measurements of the VL represents a significant change or when the difference is insignificant due to the inherent imprecision of the assay.
The implementation of international cytomegalovirus (CMV) reference materials (4, 7) will aid in the harmonization of different CMV test methods, but the question of withinassay precision will remain. Therefore, we sought to quantify the precision of a quantitative real-time PCR assay across three clinical laboratories that use standardized procedures, analyte-specific reagents (ASRs), instruments, calibrators, and specimen requirements. Second, we analyzed the data to determine whether precision varied over the analytical measuring range (AMR). Finally, we determined repeatability (withinchallenge precision for each site) and reproducibility (withinchallenge precision among all sites) of the assay at three analyte levels over time.
Over a 6-month period, four challenges of blinded split samples (n ϭ 180 in total) were sent to three testing sites within Mayo Medical Laboratories and tested as a part of routine diagnostic runs. Sample group 1 (SG1) was composed of whole virus suspended in a commutable EDTA plasma matrix (AcroMetrix, part of Life Technologies, Benicia, CA). Sample group 2 (SG2) was normal human EDTA plasma spiked with a high CMV VL patient specimen.
Challenges were sent on days 0, 14, 99, and 178 (Table 1) . Challenges sent to each site on days 0 and 14 contained only samples from SG1, comprising four CMV levels (0, 3.7, 4.7, and 5.7 log 10 copies/ml), each level in triplicate for each site. Each replicate was tested once, yielding 9 data points for each level on each day. The day 99 challenge was the same for days 0 and 14 but also included SG2 material at 5.8 log 10 copies/ml, also in triplicate for each site. The day 178 challenge was the same as day 99 but included two additional levels of SG2 (4.2 and 4.5 log 10 copies/ml), each in triplicate for each site. Overall, 180 samples were tested, including 36 data points for each level of SG1 (n ϭ 144) and 9 or 18 points for each level of SG2 (n ϭ 36).
The assay was a laboratory-developed test using LightCycler CMV UL54 primer/hybridization probes (ASRs) (Roche Diagnostics, Indianapolis, IN) as described by Razonable et al (11) , targeting the polymerase gene. Briefly, extraction of the samples (0.2 ml input) was performed using a MagNA Pure LC total nucleic acid isolation kit on a MagNA Pure LC instrument (Roche Diagnostics, Indianapolis, IN) with 0.1 ml elution. The reaction volume was composed of 15 l master mix (1ϫ Roche FastStart DNA Master HybProbe) and 5 l sample extract with 45 cycles of PCR using a LightCycler 2.0 instrument (Roche Diagnostics). The assay was calibrated using the CMV UL54 template set (Roche Diagnostics). The analytical measuring range was 3.3 to 8.3 log 10 copies/ml.
All results were qualitatively correct, and 96% of specimens were within 0.50 log 10 copies/ml of the overall mean value of each respective analyte level. To determine the overall precision, data from SG1 samples was used because this material was sent with each of the four challenges. The consistency of the materials, number of replicates, and time frame of testing make for a robust data set for statistical analysis. Standard deviations (SDs) adjusted for differences between analyte group levels were estimated with the square root of the mean squared error (RMSE) from analysis-of-variance (ANOVA) models calculated using JMP software (2008; SAS Institute Inc., Cary, NC), and the overall precision in terms of SD was 0.18 log 10 copies/ml (Table 1) .
To investigate the relationship of precision across the AMR, the second sample set, SG2, was also included. Interestingly, the SG1 and SG2 data had opposite trends in terms of precision versus AMR (Fig. 1) . Part of the discrepancy might be due to the materials used (SG1 samples were a commercial product; SG2 samples were spiked specimens). The highest level (5.8 log 10 copies/ml) of the SG2 data had three potential outliers, all from one challenge at one site. Including those three points with all data from SG1 and SG2, the Brown-Forsythe test of equivalence (1) indicated that at least one of the SDs was not equal (P ϭ 0.001), with the outlying SD being at the 5.8 log 10 copies/ml level, as expected. Omitting these three points changed the Brown-Forsythe test to nonsignificance (P ϭ 0.133) ( Table 1 ). Our interpretation was that these three points were outliers, since their consideration has such a strong bearing on the overall analysis. Omitting all results from the SG2 5.8 log 10 copies/ml level (and thus avoiding the question of outliers) yielded a result of no difference by the Brown-Forsythe test (P ϭ 0.091). Thus, the results from SG1 and SG2 demonstrated that the precision of the assay was not different among the different analyte levels in the AMR.
The relationship of precision over the AMR has implications for the reporting of results if a laboratory wants to include a confidence interval. Since the standard deviation did not demonstrate a significant difference over the AMR, the same confidence interval may be applied to any result that is reported within the AMR. In our laboratories, we report both a log and an integer value. We also include a 95% confidence interval to help clinicians determine if an observed change in VL between consecutive measurements exceeds the inherent variability of the assay.
Repeatability (within-site precision) and reproducibility (across-site precision) were tracked over the four challenges for the SG1 samples. Repeatability (a pooled SD calculated as the square root of the average of the site-specific variances, for each day at each level) was generally less than 0.15 log 10 copies/ml. Reproducibility (calculated as the SD of all results from all sites, for each level on each day) was generally less than 0.25 log 10 copies/ml.
One advantage of SG1 was that it was commercially prepared material, prepared with good manufacturing practices, and was purported to be a commutable material (i.e., it should behave the same as a patient specimen and give similar results by different methods that share a calibration). The use of commutable calibrators has been shown to increase agreement between laboratories (2). The disadvantage of SG1 was that it may not always accurately represent patient specimens. The SG2 data similarly suffered from the fact that although the samples were derived from positive patient material, they remain a constructed sample set, and there were fewer data points for the analyte levels in SG2. Also, our study did not address biological variation (i.e., variability of VL due to host factors). In HIV-1 infections, the biological variability is thought to contribute about 0.3 log 10 copies/ml to the 0.5-log 10 copies/ml threshold that is considered the minimum significant change (3, 6, 8) .
This study design may demonstrate a best-case scenario for multisite comparability of a quantitative laboratory-developed assay. The primary study outcome provides a standard deviation of 0.18 log 10 copies/ml as a point of reference for the standardization of laboratory-developed tests among multiple sites. This should be helpful as laboratories move to standardize calibration and reporting units and set acceptance criteria based on the World Health Organization International Standard for CMV and a forthcoming CMV standard reference material from the National Institute of Standards and Technology (4, 7). 
